US 12,343,327 B2
Injectable formulations
Marie Claire Layzell, London (GB); and James Maxwell Rennie, London (GB)
Assigned to Cybin UK Ltd, London (GB)
Filed by CYBIN UK LTD, London (GB)
Filed on Jun. 13, 2022, as Appl. No. 17/806,526.
Application 17/806,526 is a continuation of application No. 17/459,284, filed on Aug. 27, 2021, granted, now 11,406,619.
Application 17/459,284 is a continuation in part of application No. 17/006,115, filed on Aug. 28, 2020, abandoned.
Claims priority of application No. 2013571 (GB), filed on Aug. 28, 2020.
Prior Publication US 2022/0313660 A1, Oct. 6, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4045 (2006.01); A61K 47/02 (2006.01); A61K 47/12 (2006.01)
CPC A61K 31/4045 (2013.01) [A61K 47/02 (2013.01); A61K 47/12 (2013.01)] 19 Claims
 
1. A pharmaceutical formulation suitable for injection, comprising:
a salt of a dimethyltryptamine compound which is substituted with deuterium at one or more positions selected from the α, β and dimethyl carbon atoms;
a buffer which is separate to the salt; and
water,
wherein the formulation has a pH of about 3.5 to about 6.5 and an osmolality of about 250 mOsm/Kg to about 350 mOsm/Kg, and
wherein the formulation has an oxygen content of less than 2 ppm.